Top Investments: Marriott Vacations Worldwide Corp. (NYSE:VAC), Caterpillar Inc. (NYSE:CAT), Qumu Corporation (NASDAQ:QUMU), Transgenomic Inc. (NASDAQ:TBIO), Epizyme (NASDAQ:EPZM)


Marriott Vacations Worldwide Corp. (NYSE:VAC) shares fell -0.05% in last trading session and ended the day at $91.70. VAC Gross Margin is 54.70% and its has a return on assets of 4.00%. Marriott Vacations Worldwide Corp. (NYSE:VAC) quarterly performance is 14.06%. It was reported on 19 June, that Marriott Vacations Worldwide Corp. (NYSE:VAC) is buying 240 rooms at the Waikoloa Beach Marriott Resort & Spa on the Big Island of Hawaii with plans to convert these rooms into 112 time-share units, according to public documents.

Caterpillar Inc. (NYSE:CAT) shares decreased -1.03% in last trading session and ended the day at $83.95. CAT Gross Margin is 27.20% and its has a return on assets of 4.60%. Caterpillar Inc. (NYSE:CAT) quarterly performance is 6.29%. Caterpillar Inc. (NYSE:CAT) announced plans Wednesday to place 35 full-time Caterpillar production employees at its Pontiac plant on indefinite layoff while releasing 10 supplemental workers, effective July 20.

On 01 July, Qumu Corporation (NASDAQ:QUMU) shares moved down -5.83% and was closed at $7.76. QUMU EPS growth in last 5 year was -37.10%. Qumu Corporation (NASDAQ:QUMU) year to date (YTD) performance is -43.23%. Qumu Corporation (NASDAQ:QUMU) on 25 June, announced a sales partnership with Fujitsu, one of the world’s foremost IT service providers and the number one IT service provider in Japan.

Transgenomic Inc. (NASDAQ:TBIO) shares moved down -6.59% in last trading session and ended the day at $1.56. TBIO Gross Margin is 37.40% and its has a return on assets of -44.30%. Transgenomic Inc. (NASDAQ:TBIO) quarterly performance is 5.41%. Transgenomic Inc. (NASDAQ:TBIO) announced that it has entered into a definitive purchase agreement to raise gross proceeds of approximately $3.0 million in a private placement financing. Crede Capital Group, LLC, a Los Angeles-based family office, subscribed for all but 28,000 shares in the financing.

Epizyme, Inc. (NASDAQ:EPZM) caters to the Healthcare space. Its weekly performance is -4.32%. On the last day of trading company shares ended up $23.28. Epizyme, Inc. (NASDAQ:EPZM) distance from 50-day simple moving average (SMA50) is 19.72%. Epizyme, Inc. (NASDAQ:EPZM) on June 20, 2015, released results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful clinical activity when used as an oral monotherapy in patients with advanced B-cell non-Hodgkin lymphomas (NHL) and solid tumors. In NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, including a partial response in the first treated patient with an EZH2 tumor mutation.


Leave a Reply

Your email address will not be published. Required fields are marked *